<DOC>
	<DOC>NCT00294060</DOC>
	<brief_summary>The P3 Study is a United States post market study to gather data on clinical status, primary indications, device therapy choices, clinical management and outcomes for patients with implantable pacemakers.</brief_summary>
	<brief_title>P3: Pacemaker Patient Profiling Study</brief_title>
	<detailed_description />
	<mesh_term>Bradycardia</mesh_term>
	<criteria>Patient meets Class I / Class II indications for pacing Patient implanted with one of the following marketapproved single or dual chamber Medtronic devices: EnRhythm™, EnPulse®, Kappa® 700, Kappa® 900, Vitatron Clarity™, Vitatron Selection® AFm, Vitatron CSeries, Vitatron TSeries, or the AT500™ DDDR Pacing System Patient is enrolled in a device or cardiovascular drug study that affects treatment and/or study device programming Patient whose life expectancy is less than two years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Pacemaker</keyword>
	<keyword>Bradycardia</keyword>
</DOC>